경구백신의 효율적인 적용을 위한 면역 보조제 개발
Development of adjuvant for effective oral vaccine application
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Vaccine is one of the best known and most successful applications of immunological theory to human health and it protects human life through inducing the immune response in systemic compartment. However, when we consider the fact that mucosal epithelium is exposed to diverse foreign materials including viruses, bacteria, and food antigens and protects body from entry of unwanted materials using layer of tightly joined epithelial cells,establishing the immunological barrier on the lining of mucosal surfaces is believed to be an effective strategy to protect body from unwanted antigens. Unfortunately, however, oral mucosal site, which is considered as the best target to induce mucosal immune response due to application convenience, is prone to induce immune tolerance rather than immune stimulation. Since intestinal epithelium is tightly organized, a prerequisite for successful mucosal vaccination is delivery of antigen to mucosal immune induction site including a complex system of highly specialized cells such as M cells. Consequently, development of efficient mucosal adjuvant capable of introducing antigens to mucosal immune induction site and overcome oral tolerance is an important subject in oral vaccine development. In this review, various approaches on the development of oral mucosal adjuvants being suggested for effective oral mucosal immune induction.
Abstract
Vaccine is one of the best known and most successful applications of immunological theory to human health and it protects human life through inducing the immune response in systemic compartment. However, when we consider the fact that mucosal epithelium is exposed to diverse foreign materials including viruses, bacteria, and food antigens and protects body from entry of unwanted materials using layer of tightly joined epithelial cells,establishing the immunological barrier on the lining of mucosal surfaces is believed to be an effective strategy to protect body from unwanted antigens. Unfortunately, however, oral mucosal site, which is considered as the best target to induce mucosal immune response due to application convenience, is prone to induce immune tolerance rather than immune stimulation. Since intestinal epithelium is tightly organized, a prerequisite for successful mucosal vaccination is delivery of antigen to mucosal immune induction site including a complex system of highly specialized cells such as M cells. Consequently, development of efficient mucosal adjuvant capable of introducing antigens to mucosal immune induction site and overcome oral tolerance is an important subject in oral vaccine development. In this review, various approaches on the development of oral mucosal adjuvants being suggested for effective oral mucosal immune induction.
참고문헌 (51)
- Abreu MT, "Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function", Nat Rev Immunol, 10, pp.131~144 (2010)
- Bevan MJ, "Helping the CD8 (+) T-cell response", Nat Rev Immunol, 4, pp.595~602 (2004)
- Blanco HM, "IgA response by oral infection with an attenuated Yersinia enterocolitica mutant: implications for its use as oral carrier vaccine", Vaccine, 26, pp.6497~6502 (2008)
- Brandtzaeg P, "Mucosal immunity: induction, dissemination, and effector functions", Scand J Immunol, 70, pp.505~515 (2009)
- Brandtzaeg P, "Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties", Immunol Rev, 206, pp.32~63 (2005)
- Brandtzaeg P, "Terminology:nomenclature of mucosa-associated lymphoid tissue", Mucosal Immunol, 1, pp.31~37 (2008)
- Brayden DJ, "Keynote review:intestinal Peyer’s patch M cells and oral vaccine targeting", Drug Discov Today, 10, pp.1145~1157 (2005)
- Cerutti A, "The regulation of IgA class switching", Nat Rev Immunol, 8, pp.421~434 (2008)
- Cerutti A, "The biology of intestinal immunoglobulin A responses", Immunity, 28, pp.740~750 (2008)
- Chadwick S, "Nanotechnology solutions for mucosal immunization", Adv Drug Deliv Rev, 62, pp.394~407 (2010)
- Chen D, "Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity", Vaccine, 20, pp.2671~2679 (2002)
- Chwalek M, "Structure-activity relationships of some hederagenin diglycosides: haemolysis, cytotoxicity and apoptosis induction", Biochim Biophys Acta, 1760, pp.1418~1427 (2006)
- Clark MA, "Intestinal M cells and their role in bacterial infection", Int J Med Microbiol, 293, pp.17~39 (2003)
- Duc M, "Antigen binding to secretory immunoglobulin A results in decreased sensitivity to intestinal proteases and increased binding to cellular Fc receptors", J Biol Chem, 285, pp.953~960 (2010)
- Fagarasan S, "Adap tive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis", Annu Rev Immunol, 28, pp.243~273 (2010)
- Fievez V, "Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination", Eur J Pharm Biopharm, 73, pp.16~24 (2009)
- Gebert A, "M cells in Peyer’s patches of the intestine", Int Rev Cytol, 167, pp.91~159 (1996)
- Hase K, "Uptake through glycoprotein 2 of FimH (+) bacteria by M cells initiates mucosal immune response", Nature, 462, pp.226~230 (2009)
- Holmgren J, "Mucosal immunity and vaccines", Nat Med, 11, pp.S45~S53 (2005)
- Iwasaki A, "Mucosal dendritic cells", Annu Rev Immunol, 25, pp.381~418 (2007)
- Jepson MA, "M cell targeting by lectins:a strategy for mucosal vaccination and drug delivery", Adv Drug Deliv Rev, 56, pp.511~525 (2004)
- Keljo DJ, "Quantitative determination of macromolecular transport rate across intestinal Peyer’s patches", Am J Physiol, 244, pp.G637~G644 (1983)
- Kendall MA, "Needle-free vaccine injection", pp.193~219 (2010), Handb Exp Pharmacol
- Kiyono H, "NALT- versus Peyer’s-patchmediated mucosal immunity", Nat Rev Immunol, 4, pp.699~710 (2004)
- Knoop KA, "RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium", J Immunol, 183, pp.5738~5747 (2009)
- Kopecky-Bromberg SA, "Alpha-Cgalactosylceramide as an adjuvant for a live attenuated influenza virus vaccine", Vaccine, 27, pp.3766~3774 (2009)
- Kuolee R, "M cell-targeted delivery of vaccines and therapeutics", Expert Opin Drug Deliv, 5, pp.693~702 (2008)
- Mach J, "Development of intestinal M cells", Immunol Rev, 206, pp.177~189 (2005)
- Man AL, "Macrophage migration inhibitory factor plays a role in the regulation of microfold (M) cell-mediated transport in the gut", J Immunol, 181, pp.5673~5680 (2008)
- Marra A, "Invasin-dependent and invasinindependent pathways for translocation of Yersinia pseudotuberculosis across the Peyer’s patch intestinal epithelium", Infect Immun, 65, pp.3412~3421 (1997)
- McGhee JR, "Gut lymphocyte migration: we are halfway ‘home’", Trends Immunol, 28, pp.150~153 (2007)
- Mestecky J, "Oral immunization: an update", Curr Opin Gastroenterol, 24, pp.713~719 (2008)
- Mishra N, "Recent advances in mucosal delivery of vaccines: role of mucoadhesive", biodegradable polymeric carriers, 2010, pp.20, 661~679
- Misumi S, "Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer", J Immunol, 182, pp.6061~6070 (2009)
- Nochi T, "A rice-based oral cholera vaccine induces macaque- specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity", J Immunol, 183, pp.6538~6544 (2009)
- Nochi T, "A novel M cellspecific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses", J Exp Med, 204, pp.2789~2796 (2007)
- Parrott DM, "The gut as a lymphoid organ", Clin Gastroenterol, 5, pp.211~228 (1976)
- Plotkin SA, "Vaccines: past, present and future", Nat Med, 11, pp.S5~S11 (2005)
- Ragnarsson EG, "Magnusson KE, Soderholm JD, Artursson P (2008) Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasindependent macropinocytosis", Lab Invest, 88, pp.1215~1226 (2008)
- Reed SG, "New horizons in adjuvants for vaccine development", Trends Immunol, 30, pp.23~32 (2009)
- Rynda A, "Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma 1", J Immunol, 180, pp.5187~5200 (2008)
- Siebers A, "M cells and the pathogenesis of mucosal and systemic infections", Trends Microbiol, 4, pp.22~29 (1996)
- Slutter B, "Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination", J Control Release, 138, pp.113~121 (2009)
- Sun JB, "Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit", Scand J Immunol, 71, pp.1~11 (2010)
- Takahashi I, "New horizon of mucosal immunity and vaccines", Curr Opin Immunol, 21, pp.352~258 (2009)
- Tokuhara D, "Secretory IgA- mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine", Proc Natl Acad Sci USA, 통권 : 107, pp.8794~8799 (2010)
- Tomasi Jr TB, "Characteristics of an immune system common to certain external secretions", J Exp Med, 121, pp.101~124 (1965)
- Tsuji NM, "Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells", Trends Immunol, 29, pp.532~540 (2008)
- Tyrer PC, "Receptor mediated targeting of M-cells", Vaccine, 25, pp.3204~3209 (2007)
- Wershil BK, "Gastrointestinal mucosal immunity", J Allergy Clin Immunol, 121, pp.S380~S383 (2008)
- Wu Y, "M cell-targeted DNA vaccination", Proc Natl Acad Sci USA, 통권 : 98, pp.9318~9323 (2001)